^
Association details:
Biomarker:No biomarker
Cancer:Acute Myelogenous Leukemia
Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
10/14/2020
Excerpt:
Acute Myeloid Leukemia (Age ≥18 years): Therapy for Relapsed/Refractory Disease…LDAC (category 2B)...